Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients

瞄准：由于源于先进胃的癌症的腹膜炎 carcinomatosa 与腹水在病人在它的静脉内的管理以后在血浆和腹水检验 paclitaxel 集中。方法：有腹水的二个病人在这研究由于源于胃的癌症的腹膜炎 carcinomatosa 被包括。在血浆和腹水的 paclitaxel 集中为 72 h 被调查以防 1 和 168 h 以防 2 在静脉内的管理以后。结果：在血浆的 paclitaxel 集中在管理以后立即达到顶点，在 24 h 以内在 0.1 微摩尔(85 ng/mL ) 的阀值价值下面由快速的减少列在后面。相反，在腹水的 paclitaxel 集中在管理以后为 24 h 逐渐地增加了到与在血浆发现的水平一致的水平。在 24 h 以后，在腹水和血浆的 paclitaxel 的水平变得类似，与被维持直到 72 h 追随者管理的最佳的水平。结论：在腹水的 paclitaxel 的集中在静脉内的管理以后为多达 72 h 为癌症房间的治疗在最佳的水平以内被维持。Paclitaxel 是为胃的癌症的恶意的腹水的治疗的有希望的药。

Effect of Daikenchuto (TJ-100) on abdominal bloating in hepatectomized patients

AIM: To evaluate the clinical usefulness of Daikenchuto (DKT) in hepatecomized patients. METHODS: Twenty patients were enrolled with informed consent. Two patients were excluded because of cancelled operations. The remaining 18 patients were randomly chosen for treatment with DKT alone or combination therapy of DKT and lactulose (n = 9, each group). Data were prospectively collected. Primary end points were Visual Analogue Scale (VAS) score for abdominal bloating, total Gastrointestinal Symptoms Rating Scale (GSRS) score for abdominal symptoms, and GSRS score for abdominal bloating. RESULTS: The VAS score for abdominal bloating and total GSRS score for abdominal symptoms recovered to levels that were not significantly different to preoperative levels by 10 d postoperation. Combination therapy of DKT and lactulose was associated with a significantly poorer outcome in terms of VAS and GSRS scores for abdominal bloating, total GSRS score, and total daily calorie intake, when compared with DKT alone therapy. CONCLUSION: DKT is a potentially effective drug for postoperative management of hepatectomized patients, not only to ameliorate abdominal bloating, but also to promote nutritional support by increasing postoperative dietary intake.